NASDAQ:JNCE - Jounce Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.60 -0.77 (-6.77 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$10.60
Today's Range$10.2050 - $11.64
52-Week Range$10.20 - $29.25
Volume1.57 million shs
Average Volume453,039 shs
Market Capitalization$369.34 million
P/E Ratio-18.60
Dividend YieldN/A
Beta6.41

About Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics logoJounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio3.63
Quick Ratio3.63

Price-To-Earnings

Trailing P/E Ratio-18.60
Forward P/E Ratio-9.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.64 million
Price / Sales4.81
Cash FlowN/A
Price / CashN/A
Book Value$5.18 per share
Price / Book2.05

Profitability

EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-47.73%
Return on Equity-19.90%
Return on Assets-10.22%

Miscellaneous

Employees112
Outstanding Shares32,480,000

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics (NASDAQ:JNCE) posted its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The business earned $11.20 million during the quarter, compared to analyst estimates of $13.33 million. Jounce Therapeutics had a negative return on equity of 19.90% and a negative net margin of 47.73%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Jounce Therapeutics.

What price target have analysts set for JNCE?

5 brokerages have issued 12-month target prices for Jounce Therapeutics' stock. Their predictions range from $13.00 to $35.00. On average, they expect Jounce Therapeutics' share price to reach $23.75 in the next year. View Analyst Ratings for Jounce Therapeutics.

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 59)
  • Ms. Kimberlee Cobleigh Drapkin, CFO, Treasurer & Principal Accounting Officer (Age 50)
  • Dr. Elizabeth G. Trehu M.D., Chief Medical Officer (Age 58)
  • Dr. James P. Allison Ph.D., Founder
  • Dr. Thomas F. Gajewski M.D., Ph.D., Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Has Jounce Therapeutics been receiving favorable news coverage?

News articles about JNCE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a news impact score of 0.01 on Accern's scale. They also assigned media coverage about the company an impact score of 44.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Redmile Group LLC (3.64%), BlackRock Inc. (3.52%), Omega Fund Management LLC (1.63%), venBio Select Advisor LLC (1.61%), Citadel Advisors LLC (0.90%) and Fosun International Ltd (0.49%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which institutional investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Spark Investment Management LLC, Omega Fund Management LLC, Parsons Capital Management Inc. RI, Parsons Capital Management Inc. RI, BlackRock Inc., Russell Investments Group Ltd. and Northern Trust Corp. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Citadel Advisors LLC, Redmile Group LLC, Elephas Investment Management Ltd, Dimensional Fund Advisors LP, A.R.T. Advisors LLC, JBF Capital Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $10.60.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $369.34 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (JNCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  220
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Jounce Therapeutics (NASDAQ:JNCE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Jounce Therapeutics in the last 12 months. Their average twelve-month price target is $23.75, suggesting that the stock has a possible upside of 124.06%. The high price target for JNCE is $35.00 and the low price target for JNCE is $13.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.803.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.75$31.50$29.00$29.00
Price Target Upside: 124.06% upside20.78% upside95.81% upside95.81% upside

Jounce Therapeutics (NASDAQ:JNCE) Consensus Price Target History

Price Target History for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ:JNCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018HC WainwrightSet Price TargetBuy$19.00HighView Rating Details
5/17/2018Wells FargoDowngradeOutperform ➝ Market Perform$37.00 ➝ $13.00HighView Rating Details
3/8/2018Robert W. BairdSet Price TargetBuy$35.00HighView Rating Details
11/13/2017JPMorgan ChaseSet Price TargetBuy$28.00N/AView Rating Details
6/9/2017CowenReiterated RatingBuyLowView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Jounce Therapeutics (NASDAQ:JNCE) Earnings History and Estimates Chart

Earnings by Quarter for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ:JNCE) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.13 EPS

Jounce Therapeutics (NASDAQ JNCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.37)N/AView Earnings Details
5/9/2018Q1 2018($0.31)($0.40)$13.33 million$11.20 millionViewListenView Earnings Details
3/8/2018Q4 2017($0.59)($0.34)$14.95 million$13.00 millionViewListenView Earnings Details
11/13/2017Q3 2017($0.25)($0.1270)$20.00 million$18.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.15)($0.11)$19.94 million$20.29 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.09)($0.02)$19.71 million$20.30 millionViewN/AView Earnings Details
3/10/201712/31/2016$0.04$0.05$15.00 million$20.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Jounce Therapeutics (NASDAQ:JNCE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Jounce Therapeutics (NASDAQ JNCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 43.97%
Institutional Ownership Percentage: 91.15%
Insider Trading History for Jounce Therapeutics (NASDAQ:JNCE)
Insider Trading History for Jounce Therapeutics (NASDAQ:JNCE)

Jounce Therapeutics (NASDAQ JNCE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Barbara Gayle DuncanDirectorSell2,000$28.11$56,220.002,000View SEC Filing  
3/8/2018Elizabeth TrehuInsiderSell4,545$25.06$113,897.704,545View SEC Filing  
3/8/2018Kimberlee C DrapkinCFOSell5,267$25.01$131,727.675,267View SEC Filing  
3/8/2018Richard /Ca/ MurrayCEOSell16,334$25.10$409,983.4016,334View SEC Filing  
3/5/2018Elizabeth TrehuInsiderSell4,545$21.50$97,717.504,545View SEC Filing  
3/5/2018Kimberlee C DrapkinCFOSell5,267$21.42$112,819.142,775View SEC Filing  
3/5/2018Richard /Ca/ MurrayCEOSell16,334$21.43$350,037.6216,334View SEC Filing  
1/26/2018Barbara Gayle DuncanDirectorSell4,000$25.00$100,000.004,000View SEC Filing  
2/1/2017Celgene Switzerland LlcMajor ShareholderBuy625,000$16.00$10,000,000.00View SEC Filing  
2/1/2017John Duncan HiggonsDirectorBuy6,700$16.00$107,200.0027,025View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Jounce Therapeutics (NASDAQ JNCE) News Headlines

Source:
DateHeadline
Why J.C. Penney, NetEase, and Jounce Therapeutics Slumped TodayWhy J.C. Penney, NetEase, and Jounce Therapeutics Slumped Today
finance.yahoo.com - May 18 at 10:29 AM
Jounce Therapeutics Gets Throttled, Loses 35% TodayJounce Therapeutics Gets Throttled, Loses 35% Today
finance.yahoo.com - May 18 at 10:29 AM
Jounce Therapeutics (JNCE) to Present Data from Ongoing ICONIC Trial of JTX-2011 at ASCOJounce Therapeutics (JNCE) to Present Data from Ongoing ICONIC Trial of JTX-2011 at ASCO
www.streetinsider.com - May 17 at 4:40 PM
Why Jounce Shares Are Crumbling Ahead of ASCOWhy Jounce Shares Are Crumbling Ahead of ASCO
247wallst.com - May 17 at 4:40 PM
Jounce Therapeutics (JNCE) Given a $19.00 Price Target at HC WainwrightJounce Therapeutics (JNCE) Given a $19.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 17 at 2:59 PM
Wells Fargo Downgrades Jounce Therapeutics (JNCE) to Market PerformWells Fargo Downgrades Jounce Therapeutics (JNCE) to Market Perform
www.americanbankingnews.com - May 17 at 2:54 PM
Jounce Therapeutics (JNCE) Receives Consensus Rating of "Buy" from BrokeragesJounce Therapeutics (JNCE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 10:00 AM
Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011
seekingalpha.com - May 17 at 9:21 AM
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual MeetingJounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 9:21 AM
 Analysts Expect Jounce Therapeutics (JNCE) Will Announce Quarterly Sales of $13.50 Million Analysts Expect Jounce Therapeutics (JNCE) Will Announce Quarterly Sales of $13.50 Million
www.americanbankingnews.com - May 14 at 2:51 AM
Zacks Investment Research Lowers Jounce Therapeutics (JNCE) to SellZacks Investment Research Lowers Jounce Therapeutics (JNCE) to Sell
www.americanbankingnews.com - May 12 at 5:01 PM
-$0.38 EPS Expected for Jounce Therapeutics (JNCE) This Quarter-$0.38 EPS Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - May 12 at 3:19 PM
Traders Purchase High Volume of Call Options on Jounce Therapeutics (JNCE)Traders Purchase High Volume of Call Options on Jounce Therapeutics (JNCE)
www.americanbankingnews.com - May 11 at 8:15 AM
Jounce Therapeutics Target of Unusually Large Options Trading (JNCE)Jounce Therapeutics Target of Unusually Large Options Trading (JNCE)
www.americanbankingnews.com - May 11 at 7:18 AM
Jounce Therapeutics (JNCE) Releases Quarterly  Earnings Results, Misses Expectations By $0.09 EPSJounce Therapeutics (JNCE) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - May 10 at 9:52 PM
HC Wainwright Reiterates $33.00 Price Target for Jounce Therapeutics (JNCE)HC Wainwright Reiterates $33.00 Price Target for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - May 10 at 7:05 PM
Edited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMTEdited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 9:27 AM
Jounce Therapeutics (JNCE) CEO Rich Murray on Q1 2018 Results - Earnings Call TranscriptJounce Therapeutics' (JNCE) CEO Rich Murray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:43 PM
Jounce Therapeutics misses by $0.09, misses on revenueJounce Therapeutics misses by $0.09, misses on revenue
seekingalpha.com - May 9 at 9:14 AM
Jounce Therapeutics Reports First Quarter 2018 Financial ResultsJounce Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:14 AM
Zacks: Jounce Therapeutics (JNCE) Given $33.25 Consensus Price Target by BrokeragesZacks: Jounce Therapeutics (JNCE) Given $33.25 Consensus Price Target by Brokerages
www.americanbankingnews.com - May 8 at 11:43 AM
Jounce Therapeutics (JNCE) Coverage Initiated by Analysts at HC WainwrightJounce Therapeutics (JNCE) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - April 27 at 9:27 AM
$13.50 Million in Sales Expected for Jounce Therapeutics (JNCE) This Quarter$13.50 Million in Sales Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - April 27 at 5:28 AM
-$0.31 EPS Expected for Jounce Therapeutics (JNCE) This Quarter-$0.31 EPS Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - April 25 at 3:24 AM
Zacks: Brokerages Set $33.33 Target Price for Jounce Therapeutics (JNCE)Zacks: Brokerages Set $33.33 Target Price for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - April 23 at 5:14 AM
Jounce Therapeutics (JNCE) Lowered to Sell at Zacks Investment ResearchJounce Therapeutics (JNCE) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM
Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual MeetingJounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 10:02 AM
Jounce Therapeutics (JNCE) Cut to Hold at Zacks Investment ResearchJounce Therapeutics (JNCE) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM
 Brokerages Anticipate Jounce Therapeutics (JNCE) Will Post Quarterly Sales of $13.50 Million Brokerages Anticipate Jounce Therapeutics (JNCE) Will Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - April 10 at 4:30 AM
Agios and Jounce spike on potential Celgene interestAgios and Jounce spike on potential Celgene interest
seekingalpha.com - April 9 at 4:43 PM
Jounce Therapeutics (JNCE) Expected to Post Earnings of -$0.31 Per ShareJounce Therapeutics (JNCE) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - April 8 at 3:18 AM
Jounce Therapeutics (JNCE) Downgraded to Sell at Zacks Investment ResearchJounce Therapeutics (JNCE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM
Analysts Anticipate Jounce Therapeutics (JNCE) to Post ($0.31) Earnings Per ShareAnalysts Anticipate Jounce Therapeutics (JNCE) to Post ($0.31) Earnings Per Share
www.americanbankingnews.com - April 7 at 9:55 AM
Jounce Therapeutics (JNCE) Upgraded at Zacks Investment ResearchJounce Therapeutics (JNCE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM
Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $13.50 MillionJounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - March 24 at 8:52 AM
Zacks: Jounce Therapeutics Inc (JNCE) Given $33.33 Average Price Target by BrokeragesZacks: Jounce Therapeutics Inc (JNCE) Given $33.33 Average Price Target by Brokerages
www.americanbankingnews.com - March 23 at 1:16 AM
Jounce Therapeutics Inc (JNCE) Director Sells $56,220.00 in StockJounce Therapeutics Inc (JNCE) Director Sells $56,220.00 in Stock
www.americanbankingnews.com - March 19 at 8:28 PM
Jounce Therapeutics (JNCE) Upgraded to Hold by Zacks Investment ResearchJounce Therapeutics (JNCE) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:17 AM
Contrasting Jounce Therapeutics (JNCE) & Ultragenyx Pharmaceutical (RARE)Contrasting Jounce Therapeutics (JNCE) & Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - March 14 at 12:34 PM
Charting the market recovery, Nasdaq takes flight as Dow industrials divergeCharting the market recovery, Nasdaq takes flight as Dow industrials diverge
www.marketwatch.com - March 14 at 12:16 PM
Jounce Therapeutics Inc (JNCE) Insider Elizabeth Trehu Sells 4,545 SharesJounce Therapeutics Inc (JNCE) Insider Elizabeth Trehu Sells 4,545 Shares
www.americanbankingnews.com - March 12 at 10:26 PM
Jounce Therapeutics Inc (JNCE) CFO Sells $131,727.67 in StockJounce Therapeutics Inc (JNCE) CFO Sells $131,727.67 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM
Insider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of StockInsider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of Stock
www.americanbankingnews.com - March 12 at 7:38 PM
Jounce Therapeutics (JNCE) Stock Rating Lowered by Zacks Investment ResearchJounce Therapeutics (JNCE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 11 at 4:06 PM
Robert W. Baird Reiterates $35.00 Price Target for Jounce Therapeutics (JNCE)Robert W. Baird Reiterates $35.00 Price Target for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - March 8 at 7:21 PM
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsJounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 10:30 AM
Jounce Therapeutics (JNCE) Issues Quarterly  Earnings Results, Beats Estimates By $0.02 EPSJounce Therapeutics (JNCE) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 8 at 9:16 AM
 Jounce Therapeutics Inc (JNCE) Receives Consensus Recommendation of "Strong Buy" from Brokerages Jounce Therapeutics Inc (JNCE) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 8 at 3:12 AM
Insider Selling: Jounce Therapeutics Inc (JNCE) CFO Sells 5,267 Shares of StockInsider Selling: Jounce Therapeutics Inc (JNCE) CFO Sells 5,267 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM
Insider Selling: Jounce Therapeutics Inc (JNCE) Insider Sells 4,545 Shares of StockInsider Selling: Jounce Therapeutics Inc (JNCE) Insider Sells 4,545 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM

SEC Filings

Jounce Therapeutics (NASDAQ:JNCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Jounce Therapeutics (NASDAQ:JNCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Jounce Therapeutics (NASDAQ JNCE) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.